Systemic Lupus Erythematosus Trial
common.study.values.description
“A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus”
The main objective of this study is to evaluate the safety and efficacy of ABBV-105, upadacitinib, and ABBV-599 vs placebo for the treatment of signs and symptoms of SLE in participants with moderately to severely active SLE and to define doses for further development.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - ABBV-105
ABBV-105 is administered orally as capsule
Drug - Placebo for ABBV-105
Placebo for ABBV-105 is administered orally as capsule
Drug - Upadacitinib
Upadacitinib is administered orally as a tablet
Drug - Placebo for upadacitinib
Placebo for upadacitinib is administered orally as a tablet
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
common.study.values.clinical-trial-id
NCT03978520
participant.views.study.view.id
av2p5a
